Enhancing a new treatment for pancreatic cancer using advanced technology
Official title: Improving the potency of novel PRMT5 inhibitor with nanocrystal technology to treat pancreatic cancer
Funded at Indiana University Indianapolis · NIH-11041283 · Data updated 2026-11-12
This study is looking at a new treatment for pancreatic cancer that uses tiny crystals to make a special medicine work better when combined with other common treatments, aiming to help patients live longer with fewer side effects.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $89,349 |
| NIH project number | 1R03CA283225-01A1 |
| Project ID | NIH-11041283 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have not responded well to current treatments.
✕Less likely to help
Patients with other types of cancer or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on improving a novel inhibitor of PRMT5, a protein linked to pancreatic cancer, by utilizing nanocrystal technology. The goal is to enhance the effectiveness of this treatment when combined with existing therapies like Gemcitabine and nano albumin-bound Paclitaxel. By targeting the mechanisms that contribute to cancer resistance, the research aims to provide a more potent and less toxic treatment option for patients suffering from pancreatic ductal adenocarcinoma. Patients may benefit from a new therapeutic approach that could potentially improve survival rates and reduce side effects.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for pancreatic cancer patients.
How similar studies have gone: Previous research has shown promise in targeting PRMT5 in cancer therapy, indicating that this approach could be a significant advancement in treatment.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Lu, Tao — Indiana University Indianapolis
- Study coordinator: Lu, Tao
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.